<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part3">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>3</PartID>
        <PartNumber>Part II</PartNumber>
        <PartSequenceNumber>3</PartSequenceNumber>
        <PartTitle>Chemotherapy</PartTitle>
        <PartChapterCount>6</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap13" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>13</ChapterID>
          <ChapterNumber>Chapter 13</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_13</ChapterDOI>
          <ChapterSequenceNumber>13</ChapterSequenceNumber>
          <ChapterTitle Language="En">Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>147</ChapterFirstPage>
          <ChapterLastPage>151</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>3</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_13" CorrespondingAffiliationID="Aff1_13">
              <AuthorName DisplayOrder="Western">
                <GivenName>Jonathan</GivenName>
                <FamilyName>Rosenberg</FamilyName>
              </AuthorName>
              <Contact>
                <Email>jonathan_rosenberg@dfci.harvard.edu</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_13">
              <OrgDivision>Lank Center for Genitourinary Oncology</OrgDivision>
              <OrgName>Dana-Farber Cancer Institute</OrgName>
              <OrgAddress>
                <City>Boston</City>
                <State>MA</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_13" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Increased understanding of the biology of advanced prostate cancer has yielded multiple targets that are worthy of evaluation. Multiple signaling pathways appear to play a role in the maintenance and progression of the malignant phenotype. These pathways, such as PI3 kinase/Akt pathway, the mTOR pathway, the Hsp90 pathway, and the insulin-like growth factor 1 pathway, are currently being investigated in clinical trials. Other fundamental processes such as histone deacetylation are also involved in prostate cancer progression. Testing agents targeting these pathways will provide crucial information regarding whether inhibition will yield clinical benefit for prostate cancer patients.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>mTOR inhibition</Keyword>
            <Keyword>Novel therapeutics</Keyword>
            <Keyword>Histone deacetylation</Keyword>
            <Keyword>Insulin-like growth factor 1</Keyword>
            <Keyword>HSP90</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Docetaxel chemotherapy is associated with improved overall survival in men with castration-resistant prostate cancer (CRPC). However, median survival of these patients remains under 2 years, and better options are needed. Several strategies to improve these outcomes have been pursued. Addition of novel agents to docetaxel represents one pathway forward. To date, adding another agent does not appear to add positively to docetaxel (e.g. DN101, GVAX, bevazicumab). Epidermal growth factor receptor (EGFR) pathway inhibition with erlotinib or gefitinib has been tested in phase II setting in CRPC, but does not seem to add substantial activity to docetaxel chemotherapy [<CitationRef CitationID="CR1_13">1</CitationRef>, <CitationRef CitationID="CR2_13">2</CitationRef>]. Other investigational agents target pathways that appear important in prostate cancer pathogenesis, maintenance, and progression. These therapies target the PI3 kinase/Akt pathways, the mTOR pathway, the Hsp90 pathway, insulin-like growth factor 1 pathway, and histone deacetylation. Preclinical evidence supports the importance of these molecular pathways, although clinical testing of most of these agents remains immature. This chapter will review the available data and the current clinical status of agents targeting these pathways.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>PI3 Kinase/Akt Pathways</Heading>
            <Para TextBreak="No">The tumor suppressor gene encoding phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost with high frequency in prostate cancer. This results in constitutive activation of the PI3 kinase/Akt pathway. The PI3 kinase is a complex heterodimeric molecule with multiple subcomponents which receives upstream signals from multiple receptor tyrosine kinases, including the insulin-like growth factor (IGF) receptor. These receptor tyrosine kinases activate the PI3 kinase, leading to Akt activation by PDK1 and 2. After phosphorylation by PDK1 and 2, Akt translocates to the nucleus, where it, in turn, phosphorylates many proteins to regulate diverse functions in the cell. While no activating point mutations of Akt have been identified in prostate cancer specimens, high Akt activity appears to be involved in prostate cancer growth and progression [<CitationRef CitationID="CR3_13">3</CitationRef>]. Increased Akt activity has been demonstrated in more poorly differentiated prostate tumors and predicts biochemical recurrence [<CitationRef CitationID="CR4_13">4</CitationRef>, <CitationRef CitationID="CR5_13">5</CitationRef>]. Furthermore, Akt activation has been implicated in the progression to castration resistance. In vitro studies with androgen-dependent LNCaP cells grown in the absence of androgens develop androgen-independent growth and high levels of Akt activation [<CitationRef CitationID="CR6_13">6</CitationRef>]. Akt activation was also increased in LNCaP xenografts grown in castrated mice, compared to the parental LNCaP cell line [<CitationRef CitationID="CR7_13">7</CitationRef>].</Para>
            <Para TextBreak="No">Akt and PI3 kinase inhibitors are currently under investigation in clinical trials in prostate cancer. Perifosine, an oral Akt inhibitor has been evaluated in a phase II study of patients with hormone-sensitive prostate cancer and rising PSA after definitive local therapy [<CitationRef CitationID="CR8_13">8</CitationRef>]. Twenty percent of patients treated had a reduction in PSA levels, but none had declines greater than 50%. PSA doubling time (compared to pretreatment doubling time) was not increased with perifosine treatment, and the median time to PSA progression was 6.6 months. This modest activity is insufficient to justify further single-agent testing of perifosine in prostate cancer, but combination studies with androgen deprivation therapy and chemotherapy are underway. Other Akt and PI3 kinase inhibitors are in early phase clinical trials and have not yet been specifically tested in prostate cancer.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>mTOR Inhibition</Heading>
            <Para TextBreak="No">The mammalian target of rapamycin (mTOR) lies downstream of PI3 kinase and Akt and is activated in PTEN-deleted tumors. mTOR is a serine/threonine kinase that receives signals from multiple upstream growth and nutrient sensing pathways and phosphorylates transcription factors that are critical for cell proliferation (S6K1 and 4E-BP1). mTOR inhibition using temsirolimus has demonstrated clinical benefit in patients with advanced renal cell carcinoma [<CitationRef CitationID="CR9_13">9</CitationRef>]. Preclinical testing suggests that Akt upregulation may be countered by mTOR inhibition. Transgenic mice expressing human Akt develop tumors in the ventral prostate; treatment with everolimus, an mTOR inhibitor, reverses the neoplastic phenotype [<CitationRef CitationID="CR10_13">10</CitationRef>]. Other preclinical works suggest that mTOR inhibition might restore chemotherapy sensitivity to a resistant prostate cancer cell line. PTEN-deficient PC-3 cells treated with rapamycin or temsirolimus were rendered sensitive to doxorubicin, similar to PC-3 cells with normal PTEN expression both in vitro and in vivo [<CitationRef CitationID="CR11_13">11</CitationRef>].</Para>
            <Para TextBreak="No">Agents targeting mTOR have been tested in phase II studies in prostate cancer. A pharmacodynamic study of everolimus was conducted in patients with newly diagnosed prostate cancer about to undergo radical prostatectomy [<CitationRef CitationID="CR12_13">12</CitationRef>]. Preliminary results suggest that the pharmacodynamic effects of mTOR inhibition by everolimus can be detected in prostate tumor tissue, as measured by a reduced level of phospho-S6 kinase by immunohistochemistry. In a similar fashion, oral temsirolimus was tested in newly diagnosed prostate cancer patients who were about to undergo radical prostatectomy [<CitationRef CitationID="CR13_13">13</CitationRef>]. Decreases in mTOR activation as measured by S6 kinase phosphorylation were detected in patients treated with temsirolimus, although an associated increase in phospho-Akt and phospho-mTOR was seen. These results are consistent with other research works suggesting that upstream Akt activation is observed with mTOR inhibition, and may be a mechanism of resistance [<CitationRef CitationID="CR14_13">14</CitationRef>].</Para>
            <Para TextBreak="No">In CRPC, everolimus was tested in a phase II study [<CitationRef CitationID="CR15_13">15</CitationRef>]. Preliminary results from this study demonstrated a 2.5 month time to progression without any radiographic or PSA responses. Although these results were not encouraging, the majority of these patients were a chemotherapy refractory population. Everolimus was also tested in combination with docetaxel in a phase I study using FDG-PET imaging as a pharmacodynamic endpoint [<CitationRef CitationID="CR16_13">16</CitationRef>]. The combination was tolerable at doses of everolimus 10 mg daily with docetaxel 70 mg/m<Superscript>2</Superscript> every 3 weeks, with some evidence suggesting decreased FDG-avidity associated with PSA responses.</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Hsp90 Pathway</Heading>
            <Para TextBreak="No">Hsp90 is a highly expressed molecular chaperone that is significantly upregulated during cellular stress. It plays a role in the folding, translocation, and refolding of proteins in eukaryotic cells. Hsp90 has been demonstrated to play a role in the ability of cancer cells to evade normal regulatory pathways. In particular, Hsp90 has been shown to be critical for the proper folding and processing of the androgen receptor. The ability of Hsp90 to bind to target proteins is dependent on its ability to bind and hydrolyze ATP. Inhibitors of the ATP hydrolase activity prevent Hsp90 from associating with its target proteins. In vivo, treatment of prostate cancer cells with geldanamycin, an Hsp90 inhibitor, causes loss of AR activity and degradation of AR protein [<CitationRef CitationID="CR17_13">17</CitationRef>]. Based on the loss of AR activity, degradation of the AR protein, and provocative xenograft data demonstrating significant tumor regression, geldanamycin derivatives such as 17-AAG, which are less toxic, have been tested in prostate cancer. A phase II study of 17-AAG in CRPC patients previously treated with chemotherapy, unfortunately, did not result in any patients achieving a 50% decline in PSA, and the median time to progression was only 1.8 months [<CitationRef CitationID="CR18_13">18</CitationRef>]. Other Hsp90 inhibitors, such as 17-DMAG, are currently under investigation as single agents or in combination with other therapies for the treatment of prostate cancer.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Insulin-Like Growth Factor Pathway</Heading>
            <Para TextBreak="No">Nonandrogen hormonal signaling appears to play an important role in the progression of CRPC. Of the cell membrane-associated receptor tyrosine kinases, the insulin-like growth factor 1 receptor (IGF1R) may play a key role. The IGF pathway regulates cell growth, protects cells from apoptosis, and promotes tumor cell invasion in a variety of human cancers. Clinical and epidemiological data suggest that elevated plasma IGF-1 levels are a risk factor for the development of prostate cancer and that IGF-1 increases the growth of prostate cancer cell cultures [<CitationRef CitationID="CR19_13">19</CitationRef>]. Elimination of IGF1R signaling suppresses growth and invasion in in vivo models of prostate cancer [<CitationRef CitationID="CR20_13">20</CitationRef>]. Furthermore, some androgen-dependent cell lines increase IGF1 and IGF1R expression when they develop androgen-independent growth [<CitationRef CitationID="CR21_13">21</CitationRef>, <CitationRef CitationID="CR22_13">22</CitationRef>]. Therefore, targeting the IGF1 axis may play an important role in the future treatment of CRPC.</Para>
            <Para TextBreak="No">The IGF1 axis may be targeted in multiple ways. First, the available ligand to activate the pathway may be depleted. This may be accomplished by growth hormone pathway inhibition leading to decreased IGF1 secretion, increased binding of IGF1 to its binding proteins, or antibodies targeting the IGF molecule. Somatostatin analogues that lower IGF1 have been tested in CRPC and found to be associated with modest PSA response proportions. Lantreotide was associated with ≥50% PSA declines in 20% of CRPC patients [<CitationRef CitationID="CR23_13">23</CitationRef>]. Octreotide, in combination with dexamethasone, was associated with ≥50% PSA declines in 60% of patients [<CitationRef CitationID="CR24_13">24</CitationRef>]. Further testing of somatostatin analogues is ongoing.</Para>
            <Para TextBreak="No">Second, receptor activation may be inhibited. Small-molecule tyrosine kinase inhibitors and receptor-binding antibodies may prove useful for this purpose. These are currently being tested in phase II clinical trials in prostate cancer. Meso-nordihydroguaiaretic acid (NDGA), derived from the creosote bush, inhibits the IGF1R tyrosine kinase and was observed to reduce androgen-dependent growth in in vitro studies. A phase I study with NDGA was completed in men with a rising PSA after definitive local therapy [<CitationRef CitationID="CR25_13">25</CitationRef>]. While transaminase elevations limited therapy, one of 11 patients experienced a ≥50% PSA decline, and several other patients had a prolongation of PSA doubling time. Further development of NDGA is ongoing.</Para>
            <Para TextBreak="No">Inhibition of the IGF1 receptor activation may also be achieved by binding and inactivating the receptor. The human monoclonal IgG1 antibody, IMC-A12, inhibits ligand-dependent receptor activation and is currently being tested in prostate cancer [<CitationRef CitationID="CR26_13">26</CitationRef>].</Para>
            <Para TextBreak="No">An expected toxicity associated with IGF1 inhibition would be cross-inhibition of the insulin receptor pathway and concomitant problems with hyperglycemia. The extent that this will be a concern with agents targeting this pathway remains an open question. These agents are currently being tested as single agents, and the potential for synergy with cytotoxic chemotherapy suggests that they will be tested in combinations in the future.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Histone Deacetylase Inhibitors</Heading>
            <Para TextBreak="No">Transcription of genes depends on the interaction of transcription factors, DNA, and chromatin structural elements, such as histones. Regulation of transcription is affected by histone acetylation status. Histone deacetylation is carried out by histone deacetylases, of which there are three classes: class I, which is nuclear and associated with transcriptional repression; class II, which deacetylates larger proteins in both the cytoplasm and the nucleus; and HDAC6, which is specific for histones. Inhibition of histone deacetylation, resulting in hyperacetylation, leads to transcriptional activation of repressed genes. Preclinical evaluation of histone deacetylase inhibitors has suggested the presence of significant antiprostate cancer activity, although the mechanism of cancer cell death of these agents is not entirely elucidated. HDAC inhibitor-mediated cytotoxicity may result from several different mechanisms. One pathway that may be particularly important in prostate cancer is acetylation and disruption of heat shock protein client proteins, which shuttle the androgen receptor to the nucleus.</Para>
            <Para TextBreak="No">Romidepsin (FK228) inhibits class I HDAC’s and Hsp90 function and has demonstrated preclinical evidence of efficacy in prostate cancer. Xenograft models of prostate cancer show reduced growth when treated with romidepsin, and this is potentiated in combination with docetaxel chemotherapy [<CitationRef CitationID="CR27_13">27</CitationRef>, <CitationRef CitationID="CR28_13">28</CitationRef>]. Romidepsin was tested as a single agent in a phase II study of CRPC patients not previously treated with chemotherapy. One of 21 evaluable patients elicited a radiographically confirmed partial response, and the PSA response proportion was 7% [<CitationRef CitationID="CR29_13">29</CitationRef>]. Some patients experienced periods of disease stabilization, and this agent is being tested in combination with other agents in CRPC.</Para>
            <Para TextBreak="No">Vorinostat (SAHA) also has activity in preclinical models of prostate cancer [<CitationRef CitationID="CR30_13">30</CitationRef>]. Interestingly, there seems to be reduced activity of the compound in androgen receptor-negative prostate cancer cells, such as PC-3, and suppression of androgen signaling in the presence of the androgen receptor may sensitize prostate cancer cells to vorinostat [<CitationRef CitationID="CR31_13">31</CitationRef>]. A phase II study of vorinostat alone in patients previously treated with docetaxel chemotherapy did not demonstrate significant anticancer activity [<CitationRef CitationID="CR32_13">32</CitationRef>]. In that study of heavily pretreated patients, vorinostat was associated with a short time to progression and significant toxicity. Vorinostat is being tested in androgen-dependent prostate cancer in combination with androgen deprivation, based on the preclinical data suggesting that androgen deprivation may potentiate the actions of HDAC inhibition [<CitationRef CitationID="CR33_13">33</CitationRef>]. Other HDAC inhibitors, such as LBH589 and belinostat, are being evaluated in prostate cancer as well; no clinical data is available at this time.</Para>
          </Section1>
          <Section1 ID="Sec7" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">Preclinical work has indicated that multiple biochemical pathways may play a role in the maintenance and progression of the malignant phenotype in prostate cancer, and many of these pathways may be targeted with novel agents. While none of the treatments referred to above have been proven to provide clinical benefit, further testing is ongoing.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_13.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_13">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Canil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Moore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Winquist</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>455</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>15659491</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.02.129</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXitVarsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23(3):455–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_13">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Gross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Higano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Pantuck</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>BMC Cancer</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>142</FirstPage>
                <Occurrence Type="PID">
                  <Handle>17662137</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1186/1471-2407-7-142</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gross M, Higano C, Pantuck A, et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007;7:142.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_13">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Majumder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Sellers</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Akt-regulated pathways in prostate cancer</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>24</VolumeID>
                <IssueID>50</IssueID>
                <FirstPage>7465</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>16288293</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1209096</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXht1Wis7vF</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24(50):7465–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_13">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SN</Initials>
                  <FamilyName>Malik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Brattain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Ghosh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>8</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>1168</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>11948129</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8(4):1168–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_13">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Kreisberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SN</Initials>
                  <FamilyName>Malik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Prihoda</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>15</IssueID>
                <FirstPage>5232</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15289328</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-0272</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXmtF2mtbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64(15):5232–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_13">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Murillo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DI</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>142</VolumeID>
                <IssueID>11</IssueID>
                <FirstPage>4795</FirstPage>
                <LastPage>805</LastPage>
                <Occurrence Type="PID">
                  <Handle>11606446</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/en.142.11.4795</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnslGqur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001;142(11):4795–805.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_13">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Graff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BW</Initials>
                  <FamilyName>Konicek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>McNulty</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>275</VolumeID>
                <IssueID>32</IssueID>
                <FirstPage>24500</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>10827191</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M003145200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlsl2jsrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275(32):24500–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_13">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KG</Initials>
                  <FamilyName>Chee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Longmate</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DI</Initials>
                  <FamilyName>Quinn</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial</ArticleTitle>
                <JournalTitle>Clin Genitourin Cancer</JournalTitle>
                <VolumeID>5</VolumeID>
                <IssueID>7</IssueID>
                <FirstPage>433</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>18272025</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.3816/CGC.2007.n.031</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXitVGqsrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5(7):433–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_13">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Hudes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Carducci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Tomczak</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>356</VolumeID>
                <IssueID>22</IssueID>
                <FirstPage>2271</FirstPage>
                <LastPage>81</LastPage>
                <Occurrence Type="PID">
                  <Handle>17538086</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa066838</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmtVKkurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_13">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PK</Initials>
                  <FamilyName>Majumder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PG</Initials>
                  <FamilyName>Febbo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bikoff</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>6</IssueID>
                <FirstPage>594</FirstPage>
                <LastPage>601</LastPage>
                <Occurrence Type="PID">
                  <Handle>15156201</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm1052</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXksVais7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10(6):594–601.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_13">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Grunwald</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>DeGraffenried</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Russel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WE</Initials>
                  <FamilyName>Friedrichs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Ray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hidalgo</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <IssueID>21</IssueID>
                <FirstPage>6141</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>12414639</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XosF2ms78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62(21):6141–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_13">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Lerut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Roskams</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Goossens</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC)</ArticleTitle>
                <JournalTitle>J Clin Oncol (Meeting Abstracts)</JournalTitle>
                <VolumeID>23</VolumeID>
                <IssueID>16_suppl</IssueID>
                <FirstPage>3071</FirstPage>
              </BibArticle>
              <BibUnstructured>Lerut E, Roskams T, Goossens E, et al. Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC). J Clin Oncol (Meeting Abstracts) 2005;23(16_suppl):3071.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_13">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Efstathiou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Tsavachidou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Wen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Troncoso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GB</Initials>
                  <FamilyName>Mills</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Logothetis</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with Temsirolimus with or without androgen ablation</ArticleTitle>
                <JournalTitle>J Clin Oncol (Meeting Abstracts)</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>15_suppl</IssueID>
                <FirstPage>5071</FirstPage>
              </BibArticle>
              <BibUnstructured>Efstathiou E, Tsavachidou D, Wen S, Troncoso P, Mills GB, Logothetis CJ. Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with Temsirolimus with or without androgen ablation. J Clin Oncol (Meeting Abstracts) 2008;26(15_suppl):5071.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_13">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>O’Reilly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Rojo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Q-B</Initials>
                  <FamilyName>She</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>1500</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16452206</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-05-2925</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Reilly KE, Rojo F, She Q-B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_13">
              <CitationNumber>15</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Armstrong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Creel</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <BookTitle>A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer. Proceedings of the Genitourinary Cancers Symposium</BookTitle>
                <BibComments>Abstract 181</BibComments>
              </BibBook>
              <BibUnstructured>George DA, Armstrong AJ, Creel P, et al. A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer. Proceedings of the Genitourinary Cancers Symposium 2008: Abstract 181.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_13">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity</ArticleTitle>
                <JournalTitle>J Clin Oncol (Meeting Abstracts)</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>15_suppl</IssueID>
                <FirstPage>5069</FirstPage>
              </BibArticle>
              <BibUnstructured>Ross RW, Manola J, Oh WK, et al. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol (Meeting Abstracts) 2008;26(15_suppl):5069.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_13">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Smaletz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Horse-Grant</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2002</Year>
                <ArticleTitle Language="En">Epothilone B analogue (BMS-247550) with estramustine phosphate in patients with progressive castrate-metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Proc Am Soc Clin Oncol</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>732</FirstPage>
              </BibArticle>
              <BibUnstructured>Smaletz O, Kelly WK, Horse-Grant D, et al. Epothilone B analogue (BMS-247550) with estramustine phosphate in patients with progressive castrate-metastatic prostate cancer. Proc Am Soc Clin Oncol 2002;21:732.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_13">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EI</Initials>
                  <FamilyName>Heath</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Hillman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>U</Initials>
                  <FamilyName>Vaishampayan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol (Meeting Abstracts)</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>18_suppl</IssueID>
                <FirstPage>15553</FirstPage>
              </BibArticle>
              <BibUnstructured>Heath EI, Hillman D, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):15553.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_13">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Stampfer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>279</VolumeID>
                <IssueID>5350</IssueID>
                <FirstPage>563</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9438850</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.279.5350.563</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXotVOqsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279(5350):563–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_13">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Odman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LM</Initials>
                  <FamilyName>Higgins</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <IssueID>8</IssueID>
                <FirstPage>3065</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="PID">
                  <Handle>15837762</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-1586</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjtlejtb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11(8):3065–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_13">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Krueckl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Sikes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Edlund</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <IssueID>23</IssueID>
                <FirstPage>8620</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15574769</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-2446</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVCjs73J</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Krueckl SL, Sikes RA, Edlund NM, et al. increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64(23):8620–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_13">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kiyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Morrison</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Zellweger</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>63</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>3575</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>12839944</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXltVGrur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kiyama S, Morrison K, Zellweger T, et al. castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63(13):3575–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_13">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Maulard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Richaud</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Droz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Jessueld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Dufour-Esquerre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Housset</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>36</VolumeID>
                <IssueID>3</IssueID>
                <FirstPage>259</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>7540120</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00685857</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2MzgtVejtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerre F, Housset M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995;36(3):259–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_13">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Koutsilieris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CS</Initials>
                  <FamilyName>Mitsiades</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Bogdanos</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>10</VolumeID>
                <IssueID>13</IssueID>
                <FirstPage>4398</FirstPage>
                <LastPage>405</LastPage>
                <Occurrence Type="PID">
                  <Handle>15240528</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-0077</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlsVWltrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Koutsilieris M, Mitsiades CS, Bogdanos J, et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;10(13):4398–405.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_13">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Harzstark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Rosenberg</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>101</VolumeID>
                <IssueID>4</IssueID>
                <FirstPage>436</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18234062</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2007.07330.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXktVagsb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 2008;101(4):436–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_13">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Rowinsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Youssoufian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Tonra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Solomon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Burtrum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Ludwig</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <IssueID>18</IssueID>
                <FirstPage>5549s</FirstPage>
                <LastPage>55s</LastPage>
                <Occurrence Type="PID">
                  <Handle>17875788</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-1109</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtVCitLrO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13(18):5549s–55s.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_13">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M-T</Initials>
                  <FamilyName>Lai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C-C</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T-Y</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F-J</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W-C</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Depsipeptide (FK228) inhibits growth of human prostate cancer cells</ArticleTitle>
                <JournalTitle>Urologic Oncology: Seminars and Original Investigations</JournalTitle>
                <VolumeID>26</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>182</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18312939</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urolonc.2007.01.020</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXivVygtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lai M-T, Yang C-C, Lin T-Y, Tsai F-J, Chen W-C. Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 2008;26(2):182–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_13">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Stanfield</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Frenkel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kabbani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J-T</Initials>
                  <FamilyName>Hsieh</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>70</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>396</FirstPage>
                <LastPage>401</LastPage>
                <Occurrence Type="PID">
                  <Handle>17826527</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2007.03.052</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang Z, Stanfield J, Frenkel E, Kabbani W, Hsieh J-T. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. Urology 2007;70(2):396–401.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_13">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Molife</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Karavasilis</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Romidepsin (FK228), a histone deacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC)</ArticleTitle>
                <JournalTitle>J Clin Oncol (Meeting Abstracts)</JournalTitle>
                <VolumeID>25</VolumeID>
                <IssueID>18_suppl</IssueID>
                <FirstPage>15507</FirstPage>
              </BibArticle>
              <BibUnstructured>Parker C, Molife R, Karavasilis V, et al. Romidepsin (FK228), a histone deacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):15507.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_13">
              <CitationNumber>30</CitationNumber>
              <BibIssue>
                <JournalTitle>Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. Clin Prostate Cancer</JournalTitle>
                <Year>2005</Year>
                <VolumeID>4</VolumeID>
                <IssueID>2</IssueID>
                <BibComments>83–5</BibComments>
              </BibIssue>
              <BibUnstructured>Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. Clin Prostate Cancer 2005;4(2):83–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_13">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Marrocco</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Tilley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Bianco-Miotto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>6</VolumeID>
                <IssueID>1</IssueID>
                <FirstPage>51</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>17218635</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1535-7163.MCT-06-0144</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXmsVarsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Marrocco DL, Tilley WD, Bianco-Miotto T, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007;6(1):51–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_13">
              <CitationNumber>32</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Bradley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Dunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Rathkopf</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <BookTitle>Vorinostat in hormone refractory prostate cancer (HRPC): trial results and IL-6 analysis. Proceedings of the Genitourinary Cancers Symposium</BookTitle>
                <BibComments>Abstract 211</BibComments>
              </BibBook>
              <BibUnstructured>Bradley DA, Dunn R, Rathkopf D, et al. Vorinostat in hormone refractory prostate cancer (HRPC): trial results and IL-6 analysis. Proceedings of the Genitourinary Cancers Symposium 2008: Abstract 211.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_13">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OW</Initials>
                  <FamilyName>Rokhlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Glover</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NV</Initials>
                  <FamilyName>Guseva</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AF</Initials>
                  <FamilyName>Taghiyev</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KG</Initials>
                  <FamilyName>Kohlgraf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MB</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Cancer Res</JournalTitle>
                <VolumeID>4</VolumeID>
                <IssueID>2</IssueID>
                <FirstPage>113</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>16513842</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1541-7786.MCR-05-0085</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhvFaisbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 2006;4(2):113–23.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
